Alma Osmanovic
Overview
Explore the profile of Alma Osmanovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
723
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marina A, Hentschel A, Stenzel M, Schara-Schmidt U, Osmanovic A, Ruck T, et al.
J Neuropathol Exp Neurol
. 2024 Jul;
83(11):979-983.
PMID: 39074165
No abstract available.
2.
Bjelica B, Wohnrade C, Osmanovic A, Schreiber-Katz O, Schuppner R, Greten S, et al.
Muscle Nerve
. 2024 Jun;
70(2):257-264.
PMID: 38872508
Introduction/aims: Spinal muscular atrophy (SMA) is a multisystem disorder. We assessed metabolic syndrome (MetS) prevalence in adults with SMA and its association with motor function, quality of life (QoL), fatigue,...
3.
Bjelica B, Wohnrade C, Cespedes I, Osmanovic A, Schreiber-Katz O, Petri S
BMC Neurol
. 2024 Feb;
24(1):67.
PMID: 38368338
Background: We aimed to describe the experience of a single neuromuscular center in Germany in treating adult spinal muscular atrophy (SMA) patients with risdiplam and to analyze motor function and...
4.
GuNTHER R, Wurster C, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, et al.
Lancet Reg Health Eur
. 2024 Feb;
39:100862.
PMID: 38361750
Background: Evidence for the efficacy of nusinersen in adults with 5q-associated spinal muscular atrophy (SMA) has been demonstrated up to a period of 16 months in relatively large cohorts but...
5.
Graessner H, Reinhard C, Baumer T, Baumgartner A, Brockmann K, Bruggemann N, et al.
Orphanet J Rare Dis
. 2024 Feb;
19(1):62.
PMID: 38347616
Background: In 2017, the German Academy for Rare Neurological Diseases (Deutsche Akademie für Seltene Neurologische Erkrankungen; DASNE) was founded to pave the way for an optimized personalized management of patients...
6.
Heinrich F, Cordts I, GuNTHER R, Stolte B, Zeller D, Schroter C, et al.
J Neurol
. 2023 Jun;
270(10):4922-4938.
PMID: 37356024
Background And Objectives: Motor Neuron Diseases (MND) are rare diseases but have a high impact on affected individuals and society. This study aims to perform an economic evaluation of MND...
7.
Schreiber-Katz O, Siegler H, Wieselmann G, Kumpe M, Ranxha G, Petri S, et al.
Sci Rep
. 2023 Apr;
13(1):6240.
PMID: 37069197
Real-world data have shown mild improvement of overall motor function in adult patients treated with nusinersen, the first approved therapy for 5q-spinal muscular atrophy (SMA). However, knowledge about preferably targeted...
8.
Bjelica B, Wohnrade C, Osmanovic A, Schreiber-Katz O, Petri S
J Neurol
. 2023 Apr;
270(7):3616-3622.
PMID: 37062018
Background: Few studies assessed the effect of nusinersen on respiratory function in adult patients with spinal muscular atrophy (SMA). The aim of this single-center study was to analyze pulmonary function...
9.
Korner S, Maximilian Koch M, Hendrik Muschen L, Seeliger T, Schreiber-Katz O, Gingele S, et al.
Clin Neurophysiol
. 2023 Mar;
149:168-175.
PMID: 36989565
Objective: This study aimed to assess cranial nerve involvement in a large adult cohort of patients with immune-mediated neuropathy undergoing immunoglobulin treatment by measuring blink reflex R1 latency prolongation in...
10.
Wohnrade C, Velling A, Mix L, Wurster C, Cordts I, Stolte B, et al.
Brain Sci
. 2023 Jan;
13(1).
PMID: 36672091
Spinal muscular atrophy (SMA) is a disabling disease that affects not only the patient’s health-related quality of life (HRQoL), but also causes a high caregiver burden (CGB). The aim of...